• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用CRISPR-Cas9进行基因组编辑以在造血干细胞中创建HPFH基因型:一种治疗镰状细胞病和β地中海贫血的方法。

Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.

作者信息

Ye Lin, Wang Jiaming, Tan Yuting, Beyer Ashley I, Xie Fei, Muench Marcus O, Kan Yuet Wai

机构信息

Department of Medicine, University of California, San Francisco, CA 94143; Institute for Human Genetics, University of California, San Francisco, CA 94143;

Department of Medicine, University of California, San Francisco, CA 94143; Institute for Human Genetics, University of California, San Francisco, CA 94143; Department of Laboratory Medicine, University of California, San Francisco, CA 94143;

出版信息

Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10661-5. doi: 10.1073/pnas.1612075113. Epub 2016 Sep 6.

DOI:10.1073/pnas.1612075113
PMID:27601644
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5035856/
Abstract

Hereditary persistence of fetal hemoglobin (HPFH) is a condition in some individuals who have a high level of fetal hemoglobin throughout life. Individuals with compound heterozygous β-thalassemia or sickle cell disease (SCD) and HPFH have milder clinical manifestations. Using RNA-guided clustered regularly interspaced short palindromic repeats-associated Cas9 (CRISPR-Cas9) genome-editing technology, we deleted, in normal hematopoietic stem and progenitor cells (HSPCs), 13 kb of the β-globin locus to mimic the naturally occurring Sicilian HPFH mutation. The efficiency of targeting deletion reached 31% in cells with the delivery of both upstream and downstream breakpoint guide RNA (gRNA)-guided Staphylococcus aureus Cas9 nuclease (SaCas9). The erythroid colonies differentiated from HSPCs with HPFH deletion showed significantly higher γ-globin gene expression compared with the colonies without deletion. By T7 endonuclease 1 assay, we did not detect any off-target effects in the colonies with deletion. We propose that this strategy of using nonhomologous end joining (NHEJ) to modify the genome may provide an efficient approach toward the development of a safe autologous transplantation for patients with homozygous β-thalassemia and SCD.

摘要

胎儿血红蛋白遗传性持续存在(HPFH)是一些个体终生都有高水平胎儿血红蛋白的一种状况。患有复合杂合β地中海贫血或镰状细胞病(SCD)以及HPFH的个体临床表现较轻。利用RNA引导的成簇规律间隔短回文重复序列相关Cas9(CRISPR-Cas9)基因组编辑技术,我们在正常造血干细胞和祖细胞(HSPCs)中删除了13 kb的β珠蛋白基因座,以模拟自然发生的西西里HPFH突变。在上游和下游断点引导RNA(gRNA)引导的金黄色葡萄球菌Cas9核酸酶(SaCas9)均递送的细胞中,靶向删除效率达到31%。与未删除的集落相比,由具有HPFH删除的HSPCs分化而来的红系集落显示出显著更高的γ珠蛋白基因表达。通过T7核酸内切酶1检测,我们在删除的集落中未检测到任何脱靶效应。我们提出,这种使用非同源末端连接(NHEJ)来修饰基因组的策略可能为开发针对纯合β地中海贫血和SCD患者的安全自体移植提供一种有效方法。

相似文献

1
Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.使用CRISPR-Cas9进行基因组编辑以在造血干细胞中创建HPFH基因型:一种治疗镰状细胞病和β地中海贫血的方法。
Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10661-5. doi: 10.1073/pnas.1612075113. Epub 2016 Sep 6.
2
Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.优化 CRISPR/Cas9 递送至人类造血干/祖细胞用于治疗性基因组重排。
Mol Ther. 2019 Jan 2;27(1):137-150. doi: 10.1016/j.ymthe.2018.10.008. Epub 2018 Oct 17.
3
Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin.通过 CRISPR 碱基编辑鉴定新型类 HPFH 突变,提高胎儿血红蛋白表达。
Elife. 2022 Feb 11;11:e65421. doi: 10.7554/eLife.65421.
4
Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.镰状细胞病患者血液经CRISPR基因组编辑后克隆的子代红细胞的细胞功能重建。
J Hematol Oncol. 2017 Jun 13;10(1):119. doi: 10.1186/s13045-017-0489-9.
5
Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.CRISPR-Cas9 系统靶向敲除 BCL11A 基因激活胎儿血红蛋白:β 地中海贫血病基因治疗的一种有前途的方法。
Eur J Pharmacol. 2019 Jul 5;854:398-405. doi: 10.1016/j.ejphar.2019.04.042. Epub 2019 Apr 27.
6
A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.一种治疗β-珠蛋白生成障碍性贫血的基因组编辑策略,该策略重现了与一种良性遗传疾病相关的突变。
Nat Med. 2016 Sep;22(9):987-90. doi: 10.1038/nm.4170. Epub 2016 Aug 15.
7
Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus.通过 CRISPR/Cas9 介导的人β-珠蛋白基因座编辑诱导胎儿血红蛋白合成。
Blood. 2018 Apr 26;131(17):1960-1973. doi: 10.1182/blood-2017-10-811505. Epub 2018 Mar 8.
8
Induction of therapeutic levels of HbF in genome-edited primary β 39-thalassaemia haematopoietic stem and progenitor cells.在经基因编辑的β39 型地中海贫血造血干祖细胞中诱导治疗水平的 HbF。
Br J Haematol. 2021 Jan;192(2):395-404. doi: 10.1111/bjh.17167. Epub 2020 Nov 20.
9
Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype.编辑 γ-珠蛋白抑制因子结合位点可恢复胎儿血红蛋白合成并纠正镰状细胞病表型。
Sci Adv. 2020 Feb 12;6(7). doi: 10.1126/sciadv.aay9392. Print 2020 Feb.
10
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.CRISPR-Cas9 基因编辑治疗镰状细胞病和 β-地中海贫血。
N Engl J Med. 2021 Jan 21;384(3):252-260. doi: 10.1056/NEJMoa2031054. Epub 2020 Dec 5.

引用本文的文献

1
Coupling CRISPR scanning with targeted chromatin accessibility profiling using a double-stranded DNA deaminase.使用双链DNA脱氨酶将CRISPR扫描与靶向染色质可及性分析相结合。
Nat Methods. 2025 Sep 11. doi: 10.1038/s41592-025-02811-2.
2
CRISPR-mediated optogene expression from a cell-specific endogenous promoter in retinal ON-bipolar cells to restore vision.通过CRISPR技术介导,在视网膜ON双极细胞中从细胞特异性内源性启动子表达光基因以恢复视力。
Front Drug Deliv. 2023 Mar 27;3:934394. doi: 10.3389/fddev.2023.934394. eCollection 2023.
3
Disrupting ZBTB7A or BCL11A binding sites reactivates fetal hemoglobin in erythroblasts from healthy and β-thalassemia/HbE individuals.破坏ZBTB7A或BCL11A结合位点可重新激活健康个体以及β地中海贫血/HbE个体成红细胞中的胎儿血红蛋白。
Sci Rep. 2025 Jul 15;15(1):25580. doi: 10.1038/s41598-025-10791-8.
4
Epigenetic Regulation of Erythropoiesis: From Developmental Programs to Therapeutic Targets.红细胞生成的表观遗传调控:从发育程序到治疗靶点
Int J Mol Sci. 2025 Jun 30;26(13):6342. doi: 10.3390/ijms26136342.
5
Structural variants in the 3D genome as drivers of disease.三维基因组中的结构变异作为疾病的驱动因素。
Nat Rev Genet. 2025 Jun 30. doi: 10.1038/s41576-025-00862-x.
6
Genome Editing in Gynecological Oncology: The Emerging Role of CRISPR/Cas9 in Precision Cancer Therapy.妇科肿瘤学中的基因组编辑:CRISPR/Cas9在精准癌症治疗中的新兴作用
Ther Innov Regul Sci. 2025 May 20. doi: 10.1007/s43441-025-00807-w.
7
Innovations in Drug Discovery for Sickle Cell Disease Targeting Oxidative Stress and NRF2 Activation-A Short Review.针对氧化应激和NRF2激活的镰状细胞病药物发现创新——简短综述
Int J Mol Sci. 2025 Apr 28;26(9):4192. doi: 10.3390/ijms26094192.
8
Beta thalassemia syndromes: New insights.β地中海贫血综合征:新见解。
World J Clin Cases. 2025 Apr 6;13(10):100223. doi: 10.12998/wjcc.v13.i10.100223.
9
CRISPR/Cas9 System as a Promising Therapy in Thalassemia and Sickle Cell Disease: A Systematic Review of Clinical Trials.CRISPR/Cas9系统作为地中海贫血和镰状细胞病的一种有前景的治疗方法:临床试验的系统评价
Mol Biotechnol. 2025 Jan 10. doi: 10.1007/s12033-025-01368-x.
10
Therapeutic Gene Editing for Hemoglobinopathies.血红蛋白病的治疗性基因编辑
Mediterr J Hematol Infect Dis. 2024 Sep 1;16(1):e2024068. doi: 10.4084/MJHID.2024.068. eCollection 2024.

本文引用的文献

1
Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.通过慢病毒转导β(A(T87Q))-珠蛋白基因对β-血红蛋白病进行基因治疗
Hum Gene Ther. 2016 Feb;27(2):148-65. doi: 10.1089/hum.2016.007.
2
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis.通过Cas9介导的原位饱和诱变对BCL11A增强子进行剖析
Nature. 2015 Nov 12;527(7577):192-7. doi: 10.1038/nature15521. Epub 2015 Sep 16.
3
Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs.转录激活样效应核酸酶(TALENs)和规律成簇间隔短回文重复序列/CRISPR相关蛋白9(CRISPR/Cas9)都直接靶向β地中海贫血来源的诱导多能干细胞(iPSCs)中的HBB基因内含子2-654(C>T)突变。
Sci Rep. 2015 Jul 9;5:12065. doi: 10.1038/srep12065.
4
In vivo genome editing using Staphylococcus aureus Cas9.使用金黄色葡萄球菌Cas9进行体内基因组编辑。
Nature. 2015 Apr 9;520(7546):186-91. doi: 10.1038/nature14299. Epub 2015 Apr 1.
5
Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells.人类造血干/祖细胞中镰状细胞病突变的校正。
Blood. 2015 Apr 23;125(17):2597-604. doi: 10.1182/blood-2014-12-615948. Epub 2015 Mar 2.
6
Reactivation of developmentally silenced globin genes by forced chromatin looping.通过强制染色质环化重新激活发育沉默的珠蛋白基因。
Cell. 2014 Aug 14;158(4):849-860. doi: 10.1016/j.cell.2014.05.050.
7
Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac.利用CRISPR/Cas9和猪尾巴病毒在患者特异性诱导多能干细胞中对β地中海贫血突变进行无缝基因校正。
Genome Res. 2014 Sep;24(9):1526-33. doi: 10.1101/gr.173427.114. Epub 2014 Aug 5.
8
Targeted genome editing in human repopulating haematopoietic stem cells.人类重编程造血干细胞中的靶向基因组编辑。
Nature. 2014 Jun 12;510(7504):235-240. doi: 10.1038/nature13420. Epub 2014 May 28.
9
Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation.安全动员成人β-地中海贫血中的 CD34+ 细胞和验证有效的珠蛋白基因转移用于临床研究。
Blood. 2014 Mar 6;123(10):1483-6. doi: 10.1182/blood-2013-06-507178. Epub 2014 Jan 15.
10
Transcription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free β-thalassemia induced pluripotent stem cells.转录激活因子样效应物核酸酶(TALEN)介导的无整合β-地中海贫血诱导多能干细胞中的基因校正。
J Biol Chem. 2013 Nov 29;288(48):34671-9. doi: 10.1074/jbc.M113.496174. Epub 2013 Oct 23.